GOSS - Gossamer Bio Inc
IEX Last Trade
0.8798
0.019 2.148%
Share volume: 590,666
Last Updated: Fri 30 Aug 2024 09:59:28 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.86
0.02
2.20%
Fundamental analysis
26%
Profitability
25%
Dept financing
11%
Liquidity
50%
Performance
25%
Performance
5 Days
-3.40%
1 Month
-7.11%
3 Months
51.61%
6 Months
-35.46%
1 Year
-17.96%
2 Year
-93.43%
Key data
Stock price
$0.88
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.45 - $1.60
52 WEEK CHANGE
-$0.16
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Sheila Gujrathi
Region: US
Website: https://www.gossamerbio.com/
Employees: 193
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.gossamerbio.com/
Employees: 193
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
gossamer bio is a san diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. founded by the former receptos executive team, gossamer bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
Recent news